摘要
目的观察5-氨基酮戊酸光动力治疗宫颈高危型HPV(HR-HPV)感染的临床疗效和安全性。方法将入组的80例宫颈HR-HPV感染患者随机分为两组,治疗组42例,予20%ALA敷药4h后用635nm红光照射30min,1周1次,共3次,治疗结束后3,6,12个月检测HPV-DNA,对照组38例,不进行任何治疗,直接进行随访。比较两组检测结果及不良反应。结果治疗组在第3个月随访时有28例HRHPV转阴,6个月为31例,12个月时增加1例转阴,但有1例患者再次出现转阳,总转阴率为73.81%。对照组3,6,12个月随访时分别有6例,8例,11例转阴,总转阴率为28.95%。治疗组转阴率明显高于对照组,差异有统计学意义(P<0.01)。治疗组患者出现轻度灼热、疼痛、分泌物增多等,未见严重不良反应。结论 5-氨基酮戊酸光动力治疗宫颈HR-HPV感染安全、有效。
Objective To observe the efficacy and safety of 5-aminolevulinic acid-photodynamic therapy（ALA-PDT）in treatment of cervical high-risk human papillom-avirus（ HR-HPV）infection.Methods Eighty patients with cervical HR-HPV infection were randomly divided into 2 groups. 42 patients were applied topically 20% ALA thermal gel for 4 hours followed by 635nm red light irradiation for 30 minutes in the treatment group. The treatment was repeated once a week, 3 times totally. The HPV was detected on the patients at 3, 6, 12 months after treatments respectively. 38 patients received no treatment in the control group. The test results and adverse reactions were compared in two groups. Results The HR-HPV of 28 cases in the treatment group was turned to be negative at the third month follow-up, of 31 cases at the sixth month, of 1 case more at the twelfth month and of 1 case was returned to be positive again. The negative conversion rate was 73.81%. The HR-HPV of 6, 8, 11 cases in control group turned negative at the third, sixth, twelfth month follow-up respectively. The negative conversion rate was 28.95%. By comparison of 3 groups, the negative conversion rate of the treatment group was significantly distinctly higher than the control group. The difference was statistically significant. The patients in the treatment group got mild heat, pain, and secretion etc, no serious adverse reactions. Conclusion Topical ALA-PDT is effective, safety treatment for cervical HR-HPV latent infection.
出处
《中国皮肤性病学杂志》
CAS
CSCD
北大核心
2017年第4期412-414,共3页
The Chinese Journal of Dermatovenereology
关键词
5-氨基酮戊酸光动力
人乳头瘤病毒
宫颈
5-Aminolevulinic acid-photodynamic therapy
Human papillomavirus
Cervix
